Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial
Jian-Xian Lin, Yan-Chang Xu, Wei Lin, Fang-Qin Xue, Jian-Xin Ye, Wei-Dong Zang, Li-Sheng Cai, Jun You, Jian-Hua Xu, Jian-Chun Cai, Yi-Hui Tang, Jian-Wei Xie, Ping Li, Chao-Hui Zheng, Chang-Ming Huang, Jian-Xian Lin, Yan-Chang Xu, Wei Lin, Fang-Qin Xue, Jian-Xin Ye, Wei-Dong Zang, Li-Sheng Cai, Jun You, Jian-Hua Xu, Jian-Chun Cai, Yi-Hui Tang, Jian-Wei Xie, Ping Li, Chao-Hui Zheng, Chang-Ming Huang
Abstract
Importance: Apatinib is a novel treatment option for chemotherapy-refractory advanced gastric cancer (GC), but it has not been evaluated in patients with locally advanced GC.
Objective: To investigate the effectiveness and safety of apatinib combined with S-1 plus oxaliplatin (SOX) as a neoadjuvant treatment for locally advanced GC.
Design, setting, and participants: This multicenter, prospective, single-group, open-label, phase 2 nonrandomized controlled trial was conducted in 10 centers in southern China. Patients with M0 and either clinical T2 to T4 or N+ disease were enrolled between July 1, 2017, and June 30, 2019. Statistical analysis was performed from December 1, 2019, to January 31, 2020.
Interventions: Eligible patients received apatinib (500 mg orally once daily on days 1 to 21 and discontinued in the last cycle) plus SOX (S-1: 40-60 mg orally twice daily on days 1 to 14; oxaliplatin: 130 mg/m2 intravenously on day 1) every 3 weeks for 2 to 5 cycles. A D2 gastrectomy was performed 2 to 4 weeks after the last cycle.
Main outcomes and measures: The primary end point was R0 resection rate. Secondary end points were the response rate, toxic effects, and surgical outcome.
Results: A total of 48 patients (mean [SD] age, 63.2 [8.2] years; 37 men [77.1%]) were enrolled in this study. Forty patients underwent surgery (38 had gastrectomy, and 2 had exploratory laparotomy), with an R0 resection rate of 75.0% (95% CI, 60.4%-86.4%). The radiologic response rate was 75.0%, and T downstaging was observed in 16 of 44 patients (36.4%). The pathological response rate was 54.2% (95% CI, 39.2%-68.6%); moreover, this rate was significantly higher in patients who achieved a radiologic response compared with those who did not (12 [80.0%] vs 1 [20.0%]; P = .03) and in those who had an Eastern Cooperative Oncology Group Performance Status score of 0 (20 [76.9%] vs 10 [45.5%]; P = .03) or had tumors located in the upper one-third of the stomach (16 [61.5%] vs 7 [31.8%]; P = .04). Patients who achieved a pathological response (vs those who did not) had significantly less blood loss (median [range]: 60 [10-200] mL vs 80 [20-300] mL; P = .04) and significantly more lymph nodes harvested (median [range]: 40 [24-67] vs 32 [19-51]; P = .04) during surgery. Postoperative complications were observed in 7 of 38 patients (18.4%). Grade 3 toxic effects occurred in 16 of 48 patients (33.3%), and no grade 4 toxic effects or preoperative deaths were observed.
Conclusions and relevance: This nonrandomized controlled trial found that apatinib combined with SOX was effective and had an acceptable safety profile as a neoadjuvant treatment for locally advanced GC. A large-scale randomized clinical trial may be needed to confirm the findings.
Trial registration: ClinicalTrials.gov Identifier: NCT03192735.
Conflict of interest statement
Conflict of Interest Disclosures: None reported.
Figures
References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
- Pyo JH, Lee H, Min BH, et al. . Long-term outcome of endoscopic resection vs. surgery for early gastric cancer: a non-inferiority-matched cohort study. Am J Gastroenterol. 2016;111(2):240-249. doi:10.1038/ajg.2015.427
- Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439-449. doi:10.1016/S1470-2045(10)70070-X
- Cunningham D, Allum WH, Stenning SP, et al. ; MAGIC Trial Participants . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20. doi:10.1056/NEJMoa055531
- NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2015. National Comprehensive Cancer Network; 2015.
- Okines AFC, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20(9):1529-1534. doi:10.1093/annonc/mdp047
- Yamada Y, Higuchi K, Nishikawa K, et al. . Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141-148. doi:10.1093/annonc/mdu472
- Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909. doi:10.1200/JCO.2005.05.0245
- Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2010;362(9):858-859. doi:10.1056/NEJMc0911925
- Bang YJ, Van Cutsem E, Feyereislova A, et al. ; ToGA Trial Investigators . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X
- Ohtsu A, Ajani JA, Bai YX, et al. . Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935-3943. doi:10.1200/JCO.2012.48.3552
- Okines AF, Ashley SE, Cunningham D, et al. . Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28(25):3945-3950. doi:10.1200/JCO.2010.29.2847
- Satoh T, Xu RH, Chung HC, et al. . Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol. 2014;32(19):2039-2049. doi:10.1200/JCO.2013.53.6136
- de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: a step forward. World J Gastroenterol. 2013;19(37):6165-6169. doi:10.3748/wjg.v19.i37.6165
- Janjigian YY, Werner D, Pauligk C, et al. . Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656-2662. doi:10.1093/annonc/mds104
- Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-1027. doi:10.1200/JCO.2005.06.081
- Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10):2003-2012. doi:10.1016/j.cellsig.2007.05.013
- Tian S, Quan H, Xie C, et al. . YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374-1380. doi:10.1111/j.1349-7006.2011.01939.x
- Li J, Qin S, Xu J, et al. . Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448-1454. doi:10.1200/JCO.2015.63.5995
- Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2010;16(44):5621-5628. doi:10.3748/wjg.v16.i44.5621
- Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11(1):1-9. doi:10.1007/s10120-007-0448-1
- World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
- Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1-19. doi:10.1007/s10120-016-0622-4
- Amin MB, Edge S, Greene F, et al. , eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017. doi:10.1007/978-3-319-40618-3
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213. doi:10.1097/
- Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
- Japanese Gastric Cancer Association . Japanese Classification of Gastric Carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101-112. doi:10.1007/s10120-011-0041-5
- Becker K, Mueller JD, Schulmacher C, et al. . Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521-1530. doi:10.1002/cncr.11660
- Roviello G, Petrioli R, Marano L, et al. . Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer. 2016;19(1):31-41. doi:10.1007/s10120-015-0537-5
- Kang YK, Kang WK, Di Bartolomeo M, et al. . Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer. September 29, 2019. Accessed November 7, 2019.
- Zheng Y, Yang X, Yan C, et al. . Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: a single-arm, open-label, phase II trial. Eur J Cancer. 2020;130:12-19. doi:10.1016/j.ejca.2020.02.013
- Martin RC II, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002;194(5):568-577. doi:10.1016/S1072-7515(02)01116-X
- Wang SY, Yeh CN, Lee HL, et al. . Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16(10):2738-2743. doi:10.1245/s10434-009-0616-0
- Nagata T, Ichikawa D, Komatsu S, et al. . Prognostic impact of microscopic positive margin in gastric cancer patients. J Surg Oncol. 2011;104(6):592-597. doi:10.1002/jso.22022
- Ychou M, Boige V, Pignon JP, et al. . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-1721. doi:10.1200/JCO.2010.33.0597
- Al-Batran SE, Hofheinz RD, Pauligk C, et al. . Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697-1708. doi:10.1016/S1470-2045(16)30531-9
- Becker K, Langer R, Reim D, et al. . Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934-939. doi:10.1097/SLA.0b013e318216f449
- Donohoe CL, O’Farrell NJ, Grant T, et al. . Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg. 2013;258(5):784-792. doi:10.1097/SLA.0b013e3182a66588
- Schuhmacher C, Gretschel S, Lordick F, et al. . Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210-5218. doi:10.1200/JCO.2009.26.6114
- Shrikhande SV, Barreto SG, Talole SD, et al. . D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol. 2013;11:31. doi:10.1186/1477-7819-11-31
- Ohtsu A, Shah MA, Van Cutsem E, et al. . Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968-3976. doi:10.1200/JCO.2011.36.2236
- Fuchs CS, Tomasek J, Yong CJ, et al. ; REGARD Trial Investigators . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-39. doi:10.1016/S0140-6736(13)61719-5
- Zhao Q, Li Y, Huang J, et al. . Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study. Pharmazie. 2017;72(4):236-240. doi:10.1691/ph.2017.6865
- Aoyama T, Nishikawa K, Fujitani K, et al. . Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017;28(8):1876-1881. doi:10.1093/annonc/mdx236
Source: PubMed